Eloxx Pharmaceuticals stock advances its clinical pipeline
Published on 10/04/2026 at 23:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eloxx Pharmaceuticals stock was last at USD 15.51 on Nasdaq on October 2, 2026, after a 1.27 percent daily decline. The clinical-stage biotech had reached a development milestone on September 11, when the first two patients entered its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome, as Yahoo Finance reported.
Kidney trial reaches first patients
The global, randomized study is designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in COL4A3, COL4A4 or COL4A5. Its initial placebo-controlled period runs for 16 weeks, with topline data expected in mid-2027 and a final readout at the end of 2027, according to Yahoo Finance.
For the market, this makes clinical execution the central valuation question. The study is testing exaluren in a rare kidney disease setting, so the next material value marker is the clinical readout rather than commercial sales.
Losses frame the valuation
Eloxx reported a Q2 2026 net loss of USD 4.502 million and diluted EPS of negative USD 0.66 for the quarter ended June 30, 2026. The Q2 loss exceeded the Q1 loss of USD 3.754 million, while revenue was USD 0 in both periods, according to the company financial data.
The balance sheet showed USD 61.960 million in cash and cash equivalents at June 30, 2026. That cash position followed the company's 2026 financing activity and gives investors a direct counterweight to the continuing operating losses.
Analyst targets stay above the quote
Investing.com lists a Strong Buy consensus from four analysts, with an average 12-month price target of USD 38.25, a high of USD 43.00 and a low of USD 32.00. The average target lies 146.6 percent above the October 2 price of USD 15.51, based on the published consensus figures.
Leerink Partners initiated coverage with an Outperform rating and a USD 32.00 target on September 18, 2026, as Yahoo Finance reported. The next earnings report is listed for November 11, 2026, by Investing.com.
Stock remains below yearly high
Eloxx Pharmaceuticals stock was last at USD 15.51 on Nasdaq on October 2, 2026, with volume of 17,711 shares and market capitalization of USD 53.3 million. The 52-week range was USD 8.20 to USD 23.40, leaving the stock 33.7 percent below its yearly high.
Eloxx Pharmaceuticals stock details
- Company: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Trading venue: Nasdaq
- Price (as of October 2, 2026): USD 15.51
- Market capitalization: USD 53.3 million (as of October 2, 2026)
- 52-week range: USD 8.20-23.40 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
Upcoming dates for Eloxx Pharmaceuticals stock
- November 11, 2026: quarterly earnings report
